While this is primarily a diagnostic biomarker study, the mechanism underlying Fibulin-2 (FBLN2) expression in meningiomas will need to be investigated with further in vitro studies such as the knock-down of the FBLN2 gene and downregulation of Fibulin-2 expression in grade II meningiomas. This evidence concerns the gene FBLN2 and meningioma.